Home > Dermatology > EADV 2019 > Spotlight on Psoriasis > ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker

ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker

Presented By
Prof. Diamant Thaçi, University of Lübeck, Germany
Conference
10:49:53pm> from conference
Trial
ESPRIT
An analysis of registry data showed that patients with moderate-to-severe psoriasis treated with adalimumab had a 58% lower standardised mortality rate compared with the general population [1]. ESPRIT is an ongoing international, prospective, observational registry evaluating the long-term safety and effectiveness of the TNF blocker adalimumab in adults with moderate-to-severe chronic plaque psoriasis under real-world conditions. Ten-year data was analysed from 6,014 psoriasis patients with collectively 28,161 person-years on adalimumab in routine clinical practice. “You may not believe it if someone tells you that you, as a dermatologist, can save patient lives by controlling psoriasis,” said Prof. Diamant Thaçi (University of Lübeck, Germany). Yet, this was exactly what the data showed: the standardised mortality ratio in participants in the ESPRIT registr...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on